JNJ stock performance?

Johnson & Johnson (JNJ) financial news, and detailed stock charts

This company symbol is outdated. Results displayed are archieved for your information

Johnson & Johnson (JNJ) Stock Summary:

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Its Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional and over-the-counter pharmaceutical products under JOHNSON?S, AVEENO, CLEAN & CLEAR, NEUTROGENA, RoC, LUBRIDERM, LISTERINE, REACH, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC names. The company?s Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology, and virology. Its products include REMICADE, a biologic to treat Crohn?s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and used to treat rheumatoid arthritis; TOPAMAX, for adjunctive and monotherapy use in epilepsy, as well as for treating migraines; PROCRIT that stimulates red blood cell production; RISPERDAL oral, a medication to treat the symptoms of schizophrenia, bipolar mania, and irritability associated with autistic behavior in indicated patients; RISPERDAL CONSTA, an injectable, and INVEGATM Extended-Release tablets to treat schizophrenia; LEVAQUIN and FLOXIN, anti-infective products; CONCERTA, a product for treating attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; and DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain. Johnson & Johnson?s Medical Devices and Diagnostics segment offers circulatory disease management, orthopaedic joint reconstruction and spinal care and sports medicine, surgical care and women?s health, minimally invasive surgical, blood glucose monitoring and insulin delivery, and diagnostic products, as well as disposable contact lenses. The company was founded in 1886 and is based in New Brunswick, New Jersey.
128,300 Employees
Last Reported Date: 04/15/14
Founded in 1885
Last $100.50 USD
Change Today +0.50 / 0.50%
Volume 2.2M
As of 10:37 AM 04/22/14 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/22/14 - $100.56
52 Week Low
06/20/13 - $82.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Request Investor Kit
JNJ:US Advanced Stock Chart

johnson & johnson (JNJ) Related Bloomberg News

Abbott First-Quarter Profit Beats Estimates on Diagnostic Tests
J&J Pharmaceutical Success Drives Increase in 2014 Forecast (1)
U.S. Retail Sales, Bank Earnings, Yellen: Week Ahead April 14-19
ADP Stripped of Top AAA Ratings on Spinoff of Auto-Dealer Unit
Reckitt Benckiser Said to Have Edge on Rivals for Merck Unit (2)

johnson & johnson (JNJ) Related News

Cruise Ships’ Germ War Spurs Hand Sanitizer Skirmish
Disney's Doc McStuffins Toys Challenge Dora the Explorer
What Do Government Agencies Have Against 23andMe, Uber, and Airbnb?
Medical Device Makers Look East

johnson & johnson (JNJ) Key Developments

Johnson & Johnson Signs Agreement with USO to Healthcare Partner

Johnson & Johnson, has entered into a multi-year agreement to be the healthcare partner of the USO.

Johnson & Johnson Announces Unaudited Consolidated Earnings Results for First Quarter of 2014

Johnson & Johnson announced unaudited consolidated earnings results for first quarter of 2014. For the quarter, the company reported sales to customers of $18,115 million, earnings before provision for taxes on income of $5,424 million, net earnings of $4,727 million or $1.64 per diluted share compared to the sales to customers of $17,505 million, earnings before provision for taxes on income of $4,261 million, net earnings of $3,497 million or $1.22 per diluted share for the same quarter a year ago.

Johnson & Johnson Provides EPS Guidance for the Year 2014

Johnson & Johnson provided EPS guidance for the year 2014. For the full year, the company increased its EPS view to a range of $5.80 to $5.90.

Johnson & Johnson financial resources

otc, otcbb, pinksheet, JNJ, ob Johnson & Johnson

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:US $100.50 USD +0.50

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merck & Co Inc $57.76 USD +0.51
Novartis AG SFr.76.60 CHF +1.90
Pfizer Inc $31.13 USD +0.27
Roche Holding AG SFr.258.40 CHF +3.50
Procter & Gamble Co/The $81.35 USD -0.21

Industry Analysis


Industry Average

Valuation JNJ Industry Range
Price/Earnings 19.1x
Price/Sales 4.0x
Price/Book 3.8x
Price/Cash Flow 18.8x
TEV/Sales 3.3x

Post a JobJobs

  • Los Angeles, CA | Johnson & Johnson
    Posted: Apr 22
  • New Brunswick, NJ | Johnson & Johnson
    Posted: Apr 22
  • California | Johnson & Johnson
    Posted: Apr 21
  • Spring House, PA | Johnson & Johnson
    Posted: Apr 22
Simply Hired

Sponsored Financial Commentaries

Sponsored Links

Archieved Financial News About Johnson & Johnson

Drugmakers Seek End or Changes to U.S. Medication Naming Rules

Read article

J&J Recall Watch: Tylenol Cold Gelcaps Pulled

Read article

Is Donald Trump Buying Bank of America?

Keywords: Is Donald Trump Buying Bank of America?, intc,bac,blk,c,cat,dia,gld,jnj,pg
Quote:  I love real estate, but good real estate is very hard to get.”  Donald Trump explained that he bought stock in  Bank of America , Citigroup, Caterpillar, Intel, Johnson & Johnson, and Procter & Gamble.  Donald Trump also said, “I love these companies.  I’ve watched them for years and I’ve never owned stock in them.  I went out yesterday and said, look I’m not getting interest on CDs, so I went out and bought some stock.” Investors should ...
Read article

Best in Breed Dividend Stocks: Portfolio Check Up

Read article

Warren Buffett's Top 6 High-Yield Stocks: Beating the Broader Market So Far in 2011

Read article

Johnson & Johnson poised to outperform during recession, says Wells Fargo

Quote: Massachusetts AG sues Ortho-Mcneil over Risperdal marketingDrug manufacturer Ortho-McNeil-Janssen, a subsidiary of Johnson & Johnson, is being sued by the Attorney General of Massachusetts for illegally marketing Risperdal, an atypical antipsychotic medication. The lawsuit alleges that Janssen promoted the drug to treat elderly dementia and a number of uses in children and adolescents when these uses had not been shown to be safe and effective and had not been approved by t...
Read article

JOHNSON & JOHNSON Files SEC form 10-Q, Quarterly Report

Read article

J&J Tentatively Agrees to Settle Risperdal Criminal Charge

Read article

If Fed Is Out of Bullets, Are Tax Cuts Only Option?

Keywords: Washington,United States,Treasurys,Treasury Department,Republicans,Political Leaders,Politics and Government,North America,Euro;EUR=X,Federal Budget (U.S.),Economy (U.S.),Democrats,Deficits,Debt,Currencies,Congress,Barack Obama,Bonds,Banking,Federal Reser
Read article

Johnson & Johnson: A Regal Dividend Stock Going Cheap

Read article

3 Dividend Powerhouses Selling at a Discount

Read article

Cramer's Watch List After Monday's Market Bloodbath

Read article

US approval of Roche melanoma drug may come early

Read article

S&P rating: Potential knock-on effects of downgrade

Keywords: S&P rating, downgrade, AAA, debt, debt ceiling, AA+, debt ceiling, debt rating, credit rating, debt, deficits,
Read article

A Look at Warren Buffett's 5 Best Bargain Stocks

Read article

Nexgen Artificial Knee Suits Targeting Zimmer Haunt Lawyers Seeking Payout

Read article

UPDATE 1-IFR-30-year debt too good to refuse with UST below 4%

Keywords: Ciara Linnane
Read article

RPT-UPDATE 1-Bayer rival Boehringer gets EU nod for Pradaxa pill

Keywords: United States
Read article

The 'Hold Forever Portfolio' Fallacy

Read article

UPDATE 3-Pfizer global drug sales fall, spark concern

Keywords: United States, Dave Zimmerman, Matthew Lewis, Michele Gershberg
Read article

You can still leave a comment about Johnson & Johnson JNJ

Besides Johnson & Johnson's Stock there is more great Microcap and Stock Market information available at